<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Summary of recommendations to managing immune-related adverse events. IrAEs: immune-related adverse events; IMP: investigational medicinal product</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>irAE</th>
    <th>Supportive Care Intervention</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Grade 1</td>
    <td>Provide symptomatic treatment</td>
   </tr>
   <tr>
    <td>Grade 2</td>
    <td>
     <p>Consider systemic corticosteroids in addition to appropriate symptomatic treatment.</p>
     <p>Steroid taper should be considered once symptoms improve to Grade 1 or less and tapered over at least 4 weeks.</p>
    </td>
   </tr>
   <tr>
    <td>Grade 3 and Grade 4</td>
    <td>
     <p>Systemic corticosteroids are indicated in addition to appropriate symptomatic treatment. May utilize 1 to 2 mg/kg prednisone or equivalent per day.</p>
     <p>Steroid taper should be considered once symptoms improve to Grade 1 or less and tapered over at least 4 weeks.</p>
     <p>Consider referral to organ-specific specialist (i.e. gastroenterologist, hepatologist, respiratory physician, endocrinologist) for any grade 3–4 irAEs, in order to evaluate substitution treatments and immune-modulating agents, such as anti-TNFα of other immune suppressants.</p>
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
